With the end of the Brexit transition period fast approaching, life sciences companies need to be ready for some major changes to drug regulations as well as the impact of new border and customs controls on the flow of medicines between Great Britain, Northern Ireland and the EU. In Vivo looks at what is at stake, and what still needs to be done, as the UK prepares to leave the EU single market and customs union at the beginning of 2021.
Whatever the outcome of the protracted and often painful negotiations on the future UK-EU trade and security relationship, the life sciences companies in the UK will be entering a very different regulatory landscape in January.
On the positive side, the UK will have its own, fully standalone medicines and medical devices regulator in the form of a strengthened Medicines and Healthcare products Regulatory Agency (MHRA)...